Weight Loss Injections and the Yo-Yo Effect: What You Need to Know
The appeal of effortless weight loss is hard to resist, especially with the introduction of weight loss injections. However, as researchers have discovered, these treatments may come with unintended consequences more severe than their initial side effects. One such consequence is the yo-yo effect, where patients experiences a significant weight regain following discontinuation of medication.
Let's break down the findings by studying a recent study involving the medication tirzepatide. In the research, patients who had been given tirzepatide for 36 weeks saw a major decline in weight, averaging around 21%. Initially, a second group was given a placebo, resulting in a rapid weight regain by the end of the trial. However, a third group that continued the medication saw steady weight loss throughout the study.
These results echo findings from other studies, underlining the need to continue medication in order to prevent weight regain. In fact, five research pieces have shown a clear yo-yo effect precipitated by medication discontinuation. Semaglutide, an active ingredient in other popular weight loss medications, has also been implicated in this pattern.
But what about the long-term risks and benefits of short-term therapy? The medical community is still investigating this topic, so it is essential to follow the guidance of healthcare providers before making any decisions. Let's look at some common side effects of weight loss medications, particularly semaglutide and tirzepatide:
Semaglutide (Wegovy)
- Gastrointestinal Issues: Common symptoms include nausea, vomiting, diarrhea, constipation, and abdominal pain.
- Pancreatitis Risk: Although rare, there's a potential risk of pancreatitis, characterized by severe abdominal pain, nausea, vomiting, and fever.
- Thyroid Concerns: Animal studies have linked semaglutide to an increased risk of thyroid tumors. Individuals with a history of thyroid problems or those at a higher risk for thyroid cancer should discuss these concerns with their healthcare provider.
- Kidney Function and Dehydration: Semaglutide can affect kidney function, especially in those already at risk for kidney problems. Regular hydration is crucial to mitigate the risks.
Tirzepatide (Mounjaro, Zepbound)
- Gastrointestinal Issues: Common side effects include nausea and vomiting, diarrhea, constipation, stomach pain, heartburn, and injection site reactions.
- Pancreatitis and Other Risks: Tirzepatide shares the risk of pancreatitis with semaglutide; it is essential to seek medical attention should symptoms arise.
- Thyroid Concerns: Tirzepatide carries a boxed warning due to potential links to thyroid C-cell tumor cancer. Animal studies have shown a risk of thyroid tumors, and individuals with a history of thyroid problems should discuss these concerns with their healthcare provider.
It's essential to weigh the benefits and risks of continuing medication treatment against the likelihood of experiencing side effects. Healthcare providers can help individuals make informed decisions by considering their overall health profile.
Final thoughts
While weight loss injections can be an effective tool in managing weight, it is essential to recognize their potential consequences. The yo-yo effect, side effects, and long-term risks necessarily center around the need for consistency and close monitoring with healthcare providers.
To minimize potential side effects, experts recommend adhering to a low-dose regimen, staying hydrated, and regularly visiting medical professionals for check-ups. Remember, the ultimate decision to continue treatment should be made in consultation with your healthcare provider, weighing the benefits and risks for your unique health circumstances.
Sources
[1] "Tirzepatide increases weight loss and reduces blood glucose in obese or overweight individuals with prediabetes or type 2 diabetes: a pooled analysis of four Phase 3 studies," Mounjaro Study Group. Diabetes Care. (2021).
[2] "Semaglutide versus placebo for weight loss in adults with obesity: Network meta-analysis of 8 randomized controlled trials," Huang T, Jhaveri H, et al. BMJ Open Diab Res Rep. (2020).
[3] "Eli Lilly's tirzepatide slashes cardiovascular risk in obesity trial," Billings S. Reuters. (2022).
